Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126139612 | 12613961 | 2 | F | 20160713 | 20160810 | 20160802 | 20160817 | EXP | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-48999BI | BOEHRINGER INGELHEIM | 32.53 | YR | M | Y | 79.00000 | KG | 20160817 | MD | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126139612 | 12613961 | 1 | PS | EMPAGLIFLOZIN | EMPAGLIFLOZIN | 1 | Oral | 204629 | TABLET | ||||||||||
| 126139612 | 12613961 | 2 | SS | HUMALOG | INSULIN LISPRO | 1 | Other | 100 U | U | 0 | 100 | IU | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126139612 | 12613961 | 1 | Diabetes mellitus |
| 126139612 | 12613961 | 2 | Type 1 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126139612 | 12613961 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126139612 | 12613961 | Hypoglycaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126139612 | 12613961 | 1 | 20160713 | 0 | ||
| 126139612 | 12613961 | 2 | 20140114 | 0 |